Therapeutic Options
Lifestyle modifications that help patients with newly-diagnosed type 2 diabetes to improve glycaemic control and other risk factors for cardiovascular disease are the starting point for diabetes therapy.1,2 However, the progressive nature of diabetes means that islet beta-cell function will continue to deteriorate and that patients will eventually have to start therapy in addition to lifestyle changes in order to maintain HbA1c levels close to normal.3
OAD Therapy
Fast acting insulin secretagogues can be used in type 2 diabetes to achieve blood glucose control.
Learn more >
|
GLP-1
GLP-1 analogue therapy may be used in combination with OADs in type 2 diabetes.
Discover GLP-1 >
|
Basal Insulin
Treatment with a long acting insulin analogue can address basal insulin needs.
Find out how >
|
Premix Insulin
Premix insulin analogues can be used to initiate insulin therapy, to intensify treatment, or to upgrade from premix human insulin.
Take a closer look >
|
Rapid Acting Insulin
Rapid acting insulin analogues can be used to help manage post-meal blood glucose levels.
Learn more >
|
Devices
The use of modern devices may improve patient acceptance and help to overcome barriers to insulin therapy.4
Learn more >
|
Glucagon
Nearly all patients with diabetes will experience a hypoglycaemic episode at some point in their life.5 Glucagon may be used for treatment of severe hypoglycaemia.
Learn more >
|
References
1International Diabetes Federation guidelines: Global guidelines for type 2 diabetes 2005. Available at: http://www.idf.org. Accessed 21 January 2010.
2Nathan DM, Buse JB, Davidson MB et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
3Fonseca VA. Defining and characterising progression of type 2 diabetes. Br J Diab Vasc Dis 2008; 8: S3.
4Rakel RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Ther 2009; 26(9): doi 10 1007/x12325-009-0061-2.
5Strachan MWJ. Frequency, causes, and risk factors for hypoglycaemia in type 1 diabetes. In Frier BM, Fischer BM, eds. Hypoglycaemia in clinical diabetes. Chichester: John Wiley; 2007, 49-81.